36 results on '"Vij, Ravi"'
Search Results
2. A phase Ib trial of isatuximab, bendamustine, and prednisone in relapsed/refractory multiple myeloma
3. Clinical response and pathway-specific correlates following TIGIT–LAG3 blockade in myeloma: the MyCheckpoint randomized clinical trial
4. Comprehensive molecular profiling of multiple myeloma identifies refined copy number and expression subtypes
5. Epigenetic regulation during cancer transitions across 11 tumour types
6. Dynamic frailty risk assessment among older adults with multiple myeloma: A population-based cohort study
7. Cross center single-cell RNA sequencing study of the immune microenvironment in rapid progressing multiple myeloma
8. Motixafortide and G-CSF to mobilize hematopoietic stem cells for autologous transplantation in multiple myeloma: a randomized phase 3 trial
9. Ixazomib, lenalidomide and dexamethasone consolidation with randomized ixazomib or lenalidomide maintenance after autologous transplant in newly diagnosed multiple myeloma
10. CS1 CAR-T targeting the distal domain of CS1 (SLAMF7) shows efficacy in high tumor burden myeloma model despite fratricide of CD8+CS1 expressing CAR-T cells
11. LocoMMotion: a prospective, non-interventional, multinational study of real-life current standards of care in patients with relapsed and/or refractory multiple myeloma
12. Treatment outcomes of triple class refractory multiple myeloma: a benchmark for new therapies
13. Ablation of VLA4 in multiple myeloma cells redirects tumor spread and prolongs survival
14. Nanoparticle T-cell engagers as a modular platform for cancer immunotherapy
15. Renal failure among multiple myeloma patients utilizing carfilzomib and associated factors in the “real world”
16. A dose-finding Phase 2 study of single agent isatuximab (anti-CD38 mAb) in relapsed/refractory multiple myeloma
17. Autologous stem cell transplant for patients with multiple myeloma between ages 75 and 78
18. Quality of life analyses in patients with multiple myeloma: results from the Selinexor (KPT-330) Treatment of Refractory Myeloma (STORM) phase 2b study
19. A pilot study of 3D tissue-engineered bone marrow culture as a tool to predict patient response to therapy in multiple myeloma
20. Co-evolution of tumor and immune cells during progression of multiple myeloma
21. DCEP and bendamustine/prednisone as salvage therapy for quad- and penta-refractory multiple myeloma
22. Maintenance therapy following salvage autologous stem cell transplant in patients with multiple myeloma
23. A phase 2 study of isatuximab monotherapy in patients with multiple myeloma who are refractory to daratumumab
24. Correction: Allogeneic transplantation in elderly patients ≥65 years with non-Hodgkin lymphoma: a time-trend analysis
25. Outcomes of patients with multiple myeloma refractory to CD38-targeted monoclonal antibody therapy
26. Impact of elotuzumab treatment on pain and health-related quality of life in patients with relapsed or refractory multiple myeloma: results from the ELOQUENT-2 study
27. Tumor microenvironment-targeted nanoparticles loaded with bortezomib and ROCK inhibitor improve efficacy in multiple myeloma
28. Evolution and structure of clinically relevant gene fusions in multiple myeloma
29. Allogeneic transplantation in elderly patients ≥65 years with non-Hodgkin lymphoma: a time-trend analysis
30. The efficacy of salvage autologous stem cell transplant among patients with multiple myeloma who received maintenance therapy post initial transplant
31. Donor body mass index does not predict graft versus host disease following hematopoietic cell transplantation
32. Inhibition of E-Selectin (GMI-1271) or E-selectin together with CXCR4 (GMI-1359) re-sensitizes multiple myeloma to therapy
33. Similar survival outcomes in patients with biclonal versus monoclonal myeloma: a multi-institutional matched case-control study
34. A multiple myeloma-specific capture sequencing platform discovers novel translocations and frequent, risk-associated point mutations in IGLL5
35. Effect of age on the pharmacokinetics of busulfan in patients undergoing hematopoietic cell transplantation; an alliance study (CALGB 10503, 19808, and 100103)
36. Phase I study of cladribine, cytarabine, granulocyte colony stimulating factor (CLAG regimen) and midostaurin and all-trans retinoic acid in relapsed/refractory AML
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.